Genzyme's Lumizyme faces delay after FDA rejection
NEW YORK (Reuters) - U.S. regulators have declined to approve Genzyme Corp's new Lumizyme treatment for Pompe disease, a setback the drugmaker said could delay its approval for six months and crimp 2009 earnings.<div class="feedflare">
<img src="http://feeds2.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA" border="0"></img> (http://feeds.reuters.com/~ff/reuters/healthNews?a=z7k2npVJrxs:Jyzn7GExZXA:yIl2AUoC8zA) <img src="http://feeds2.feedburner.com/~ff/reuters/healthNews?i=z7k2npVJrxs:Jyzn7GExZXA:F7zBnMyn0Lo" border="0"></img> (http://feeds.reuters.com/~ff/reuters/healthNews?a=z7k2npVJrxs:Jyzn7GExZXA:F7zBnMyn0Lo) <img src="http://feeds2.feedburner.com/~ff/reuters/healthNews?i=z7k2npVJrxs:Jyzn7GExZXA:V_sGLiPBpWU" border="0"></img> (http://feeds.reuters.com/~ff/reuters/healthNews?a=z7k2npVJrxs:Jyzn7GExZXA:V_sGLiPBpWU)
</div><img src="http://feeds2.feedburner.com/~r/reuters/healthNews/~4/z7k2npVJrxs" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/healthNews/~3/z7k2npVJrxs/idUSTRE5216V020090302